What is DHU-Imaging ?
The project "Molecular Imaging and Imaging-Guided Therapy" (DHU-Imaging) combines research on molecular and interventional imaging including platforms and imaging modalities of Aix-Marseille site to promote diagnostic and therapeutic interactions for the benefit of patients.
Over the past years, public health has greatly benefited from precise and early diagnosis of diseases which are otherwise incurable or difficult to treat at later stages, as well as from early and precise post-therapeutic evaluation. More recently, medical models have evolved towards personalized concept, proposing customization of healthcare for each patient with tailored approaches based on molecular signature. On the other hand, diagnostic and therapeutic interactions are mainly driven by advances of Science and Technology in biomedical imaging, and imaging-guided therapy (IGT) assumes a pivotal role in many medical innovations with minimally invasive interventional procedures.
It is in this context that DHU-Imaging project combines APHM strengths of Departments of Imaging, Pharmacy and Pathology, in collaboration with academic and industrial partners, to promote methodological innovation, transfer and applications of (pre)clinical molecular imaging & imaging-guided therapy, from research to healthcare, in closed partnership with several medical departments.
In other words, the ambition of DHU-Imaging is to achieve the selective deposit/delivery of a diagnostic/therapeutic agent (theranostic applications) on a biological target using molecular tracers mainly revealed by isotopic labeling, and/or interventional percutaneous or endovascular procedures (IGT). On the concept of personalized medicine, theranostics will be implemented, mainly in Oncology and clinical Neurosciences.
DHU-Imaging integrates also the development and the validation of imaging biomarkers (of diagnostic and of evaluation of response to treatment), the characterization of vectorization by nanoparticles or by imaging-guided interventional procedures. Development of multimodal imaging associated with synergistic interactions between physicians and nuclear radiologists, from diagnosis to therapy, could achieve a notable benefit for the management of patients mainly in the context of oncological, neurological and vascular diseases.